Several other equities analysts also recently weighed in on MEDP. Wolfe Research downgraded shares of Medpace from an outperform rating to a peer perform rating and set a $91.00 price target on the stock. in a research note on Wednesday, May 13th. Robert W. Baird raised shares of Medpace from an underperform rating to a neutral rating and set a $83.00 target price on the stock in a research note on Monday, June 8th. Zacks Investment Research upgraded Medpace from a sell rating to a hold rating in a research report on Wednesday, May 20th. SunTrust Banks raised Medpace from a sell rating to a hold rating and increased their price target for the company from $54.00 to $85.00 in a report on Thursday, April 30th. Finally, Jefferies Financial Group lowered their price objective on Medpace from $93.00 to $75.00 and set a hold rating on the stock in a research note on Monday, March 23rd. Five research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Medpace currently has an average rating of Hold and a consensus target price of $91.14.
Shares of MEDP opened at $93.57 on Friday. The firm has a market cap of $3.31 billion, a P/E ratio of 32.27 and a beta of 1.22. Medpace has a 12 month low of $58.72 and a 12 month high of $109.09. The stock’s 50 day moving average is $88.96 and its two-hundred day moving average is $85.82. The company has a current ratio of 0.89, a quick ratio of 0.89 and a debt-to-equity ratio of 0.07.
Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Tuesday, April 28th. The company reported $0.76 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.77 by ($0.01). Medpace had a net margin of 12.37% and a return on equity of 16.96%. The company had revenue of $230.88 million for the quarter, compared to analysts’ expectations of $226.23 million. During the same period in the previous year, the business earned $0.64 earnings per share. The business’s revenue for the quarter was up 15.0% on a year-over-year basis. Equities research analysts forecast that Medpace will post 2.32 EPS for the current year.
Several hedge funds and other institutional investors have recently bought and sold shares of MEDP. Wasatch Advisors Inc. raised its stake in shares of Medpace by 26.9% in the first quarter. Wasatch Advisors Inc. now owns 2,290,382 shares of the company’s stock valued at $168,068,000 after acquiring an additional 485,397 shares in the last quarter. State Street Corp increased its holdings in Medpace by 7.8% during the 1st quarter. State Street Corp now owns 859,618 shares of the company’s stock worth $63,079,000 after purchasing an additional 62,312 shares during the period. Fuller & Thaler Asset Management Inc. raised its position in Medpace by 27.6% in the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 726,816 shares of the company’s stock valued at $53,334,000 after purchasing an additional 157,308 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of Medpace by 23.7% in the 4th quarter. Renaissance Technologies LLC now owns 586,088 shares of the company’s stock valued at $49,267,000 after buying an additional 112,100 shares during the period. Finally, Geode Capital Management LLC grew its position in shares of Medpace by 5.5% during the first quarter. Geode Capital Management LLC now owns 450,923 shares of the company’s stock worth $33,088,000 after buying an additional 23,691 shares in the last quarter. 79.80% of the stock is owned by institutional investors and hedge funds.
Medpace Company Profile
Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.
Recommended Story: Limitations of the P/E Growth ratio
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.